Tag:

Eisai

Latest Headlines

Latest Headlines

Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap

Dieting and exercise to lose weight is more effective when done with support--and weight-loss drugmakers have taken that to heart in marketing their treatments. But according to a recent Journal of Public Policy & Marketing article, lifestyle support isn't enough. Drugmakers may want to look to their advertising pitches, too.

Leading Japan drug firms team up with AZ on parasitic disease research

Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.

Eisai predicts long-awaited operating profit rise for fiscal 2015

It's been a hard fall off the patent cliff for Eisai, but after 5 long years, the company says it sees its operating profit climbing in its next fiscal year.

Eisai to boost Indian API production to cut costs

Japan's Eisai, which is trying to cut costs worldwide, says it will produce more of its active pharmaceutical ingredients (APIs) at its facilities in India. The company merged two units in India in preparation. It also intends to try to sell more generic drugs.

Japan's Eisai makes moves for Indian API manufacturing in further cost trimming

Beginning in a year or two, Eisai plans to make major active pharmaceutical ingredients for generics at its Elmed Eisai state-of-the-art plants in India and import them to Japan, part of broader recent restructuring efforts by the company to trim costs.

Japan's Eisai, Glenmark settle on Banzel patent dispute

Eisai said it and Glenmark reached a settlement of the Japan drugmaker's U.S. suit for patent infringement of its Banzel (rufinamide) epilepsy drug.

Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies

Eisai and Nihon Medi-Physics plan to work together on one of Japan's three major dementia types, termed "dementia with Lewy bodies," meaning abnormal massing of protein inside nerve cells. The research is part of a broad cascade of efforts around the globe into diagnostics and treatments for dementia-related studies.

Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq

Less than a year ago, Arena marketing partner Eisai pledged to add another 200 staffers to its rep army for obesity therapy Belviq, bringing the total force to 600. Now, though, the Japanese pharma is doing some stateside job-trimming, and the restructuring will affect Arena's med, too.

Japan's Eisai cuts 25% of U.S. commercial, services units

Japan's Eisai has decided to follow the cost-cutting trend of many of its multinational counterparts and lay off a quarter of its U.S. commercial and regional corporate services units, which currently employ about 850 people. The unit said the 200-plus staff reductions would not affect manufacturing or R&D units.

UPDATED: Struggling Eisai will slash 200-plus U.S. jobs as sales revenue slides

Japan's Eisai is taking out the budget ax and chopping more than 200 jobs out of its U.S. operations. A spokesperson for the company tells FierceBiotech tonight that the cuts will center on Eisai's commercial and regional corporate services units, which employ about 850 people. She adds: "The restructuring will not affect our manufacturing or R&D units."